Scaffold-based rhBMP-2 therapy in a rat alveolar defect model: Implications for human gingivoperiosteoplasty

Plastic and Reconstructive Surgery

Volumn 124, Issue 6, 2009, Pages 1829-1839

  Nguyen, Phuong D ^a   Lin, Clarence D ^a   Allori, Alexander C ^a   Schachar, Jeffrey S ^a   Ricci, John L ^a   Saadeh, Pierre B ^a   Warren, Stephen M ^b  

^a NEW YORK UNIVERSITY COLLEGE OF DENTISTRY   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN; CALCIUM PHOSPHATE; RECOMBINANT HUMAN BONE MORPHOGENETIC PROTEIN 2; RECOMBINANT HUMAN BONE MORPHOGENETIC PROTEIN-2; RECOMBINANT PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL; ARTICLE; BIODEGRADABLE IMPLANT; BONE DEVELOPMENT; BONE REGENERATION; CLEFT PALATE; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECT; FEMALE; GINGIVOPLASTY; HUMAN; MALE; METHODOLOGY; ORAL SURGERY; PERIOSTEUM; PHYSIOLOGY; PLASTIC SURGERY; RANDOMIZATION; RAT; RISK FACTOR; SPRAGUE DAWLEY RAT;

ABSORBABLE IMPLANTS; ALVEOLAR RIDGE AUGMENTATION; ANIMALS; BONE MORPHOGENETIC PROTEINS; BONE REGENERATION; CALCIUM PHOSPHATES; CLEFT PALATE; DISEASE MODELS, ANIMAL; FEMALE; GINGIVOPLASTY; HUMANS; MALE; ORAL SURGICAL PROCEDURES; OSTEOGENESIS; PERIOSTEUM; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; RECONSTRUCTIVE SURGICAL PROCEDURES; RISK FACTORS; TRANSFORMING GROWTH FACTOR BETA;

EID: 74049130958     PISSN: 00321052     EISSN: None     Source Type: Journal    
DOI: 10.1097/PRS.0b013e3181bf8024     Document Type: Article

References (36)

1. Moreau JL, Caccamese JF, Coletti DP, Sauk JJ, Fisher JP. Tissue engineering solutions for cleft palates. J Oral Maxillofac Surg. 2007;65:2503-2511.
2. Bajaj AK, Wongworawat AA, Punjabi A. Management of alveolar clefts. J Craniofac Surg. 2003;14:840-846.
3. McNeil CK. Orthodontic procedures in the treatment of congenital cleft palate. Dent Rec. 1950;70:126-132.
4. Grayson BH, Cutting C, Wood R. Preoperative columella lengthening in bilateral cleft lip and palate. Plast Reconstr Surg. 1993;92:1422-1423.
5. Matic DB, Power SM. Evaluating the success of gingivoperiosteoplasty versus secondary bone grafting in patients with unilateral clefts. Plast Reconstr Surg. 2008;121:1343-1353.
6. Santiago PE, Grayson BH, Cutting CB, Gianoutsos MP, Brecht LE, Kwon SM. Reduced need for alveolar bone grafting by presurgical orthopedics and primary gingivoperiosteoplasty. Cleft Palate Craniofac J. 1998;35:77-80.
7. Sato Y, Grayson BH, Garfinkle JS, Barillas I, Maki K, Cutting CB. Success rate of gingivoperiosteoplasty with and without secondary bone grafts compared with secondary alveolar bone grafts alone. Plast Reconstr Surg. 2008;121:1356-1367.
8. Heary RF, Schlenk RP, Sacchieri TA, Barone D, Brotea C. Persistent iliac crest donor site pain: Independent outcome assessment. Neurosurgery 2002;50:510-516; discussion 516-517.
9. Tessier P. Autogenous bone grafts taken from the calvarium for facial and cranial applications. Clin Plast Surg. 1982;9: 531-538.
10. Tessier P, Kawamoto H, Posnick J, Raulo Y, Tulasne JF, Wolfe SA. Complications of harvesting autogenous bone grafts: A group experience of 20,000 cases. Plast Reconstr Surg. 2005; 116:72S-73S.
11. Nguyen PD, Lin CD, Allori AC, Ricci JL, Saadeh PB, Warren SM. Establishment of a critical-sized alveolar defect in the rat: A model for human gingivoperiosteoplasty. Plast Reconstr Surg. 2009;123:817-825.
12. Akamaru T, Suh D, Boden SD, et al. Simple carrier matrix modifications can enhance delivery of recombinant human bone morphogenetic protein-2 for posterolateral spine fusion. Spine 2003;28:429-434.
13. Boyne PJ. Animal studies of application of rhBMP-2 in maxillofacial reconstruction. Bone 1996;19:83S-92S.
14. Boyne PJ, Nath R, Nakamura A. Human recombinant BMP-2 in osseous reconstruction of simulated cleft palate defects. Br J Oral Maxillofac Surg. 1998;36:84-90.
15. Wang YJ, Lin FH, Sun JS, Huang YC, Chueh SC, Hsu FY. Collagen- hydroxyapatite microspheres as carriers for bone morphogenic protein-4. Artif Organs 2003;27:162-168.
16. Carter TG, Brar PS, Tolas A, Beirne OR. Off-label use of recombinant human bone morphogenetic protein-2 (rh- BMP-2) for reconstruction of mandibular bone defects in humans. J Oral Maxillofac Surg. 2008;66:1417-1425.
17. Katayama Y, Matsuyama Y, Yoshihara H, et al. Clinical and radiographic outcomes of posterolateral lumbar spine fusion in humans using recombinant human bone morphogenetic protein-2: An average five-year follow-up study. Int Orthop. 2008;33:1061-1067.
18. McKay WF, Peckham SM, Badura JM. A comprehensive clinical review of recombinant human bone morphogenetic protein- 2 (INFUSE Bone Graft). Int Orthop. 2007;31:729-734.
19. Dickinson BP, Ashley RK, Wasson KL, et al. Reduced morbidity and improved healing with bone morphogenic protein- 2 in older patients with alveolar cleft defects. Plast Reconstr Surg. 2008;121:209-217.
20. Wolfe SA. Use of rhBMP-2 in congenital alveolar clefts. Personal communication, 2008.
21. Jia YL, Fu MK, Ma L. Long-term outcome of secondary alveolar bone grafting in patients with various types of cleft. Br J Oral Maxillofac Surg. 2006;44:308-312.
22. Urist MR, Strates BS. Bone morphogenetic protein. J Dent Res. 1971;50:1392-1406.
23. Kanczler JM, Oreffo RO. Osteogenesis and angiogenesis: The potential for engineering bone. Eur Cell Mater. 2008;15: 100-114.
24. Uludag H, D'Augusta D, Palmer R, Timony G, Wozney J. Characterization of rhBMP-2 pharmacokinetics implanted with biomaterial carriers in the rat ectopic model. J Biomed Mater Res. 1999;46:193-202.
25. Kuboki Y, Saito T, Murata M, et al. Two distinctive BMPcarriers induce zonal chondrogenesis and membranous ossification, respectively; geometrical factors of matrices for cell-differentiation. Connect Tissue Res. 1995;32:219-226.
26. Toquet J, Rohanizadeh R, Guicheux J, et al. Osteogenic potential in vitro of human bone marrow cells cultured on macroporous biphasic calcium phosphate ceramic. J Biomed Mater Res. 1999;44:98-108.
27. Arosarena O, Collins W. Comparison of BMP-2 and -4 for rat mandibular bone regeneration at various doses. Orthod Craniofac Res. 2005;8:267-276.
28. Brandäo AC, Brentegani LG, Novaes Junior AB, et al. Histomorphometric analysis of rat alveolar wound healing with hydroxyapatite alone or associated to BMPs. Braz Dent J. 2002;13:147-154.
29. Calixto RF, Teofilo JM, Brentegani LG, Lamano-Carvalho TL. Alveolar wound healing after implantation with a pool of commercially available bovine bone morphogenetic proteins (BMPs): A histometric study in rats. Braz Dent J. 2007;18: 29-33.
30. Kim HD, Valentini RF. Retention and activity of BMP-2 in hyaluronic acid-based scaffolds in vitro. J Biomed Mater Res. 2002;59:573-584.
31. Prata CA, Lacerda SA, Brentegani LG. Autogenous bone graft associated with enamel matrix proteins in bone repair. Implant Dent. 2007;16:413-420.
32. Donos N, Kostopoulos L, Karring T. Alveolar ridge augmentation using a resorbable copolymer membrane and autogenous bone grafts: An experimental study in the rat. Clin Oral Implants Res. 2002;13:203-213. (Pubitemid 41698483)
33. Donos N, Kostopoulos L, Karring T. Alveolar ridge augmentation by combining autogenous mandibular bone grafts and non-resorbable membranes. Clin Oral Implants Res. 2002;13: 185-191.
34. Alberius P, Dahlin C, Linde A. Role of osteopromotion in experimental bone grafting to the skull: A study in adult rats using a membrane technique. J Oral Maxillofac Surg. 1992; 50:829-834.
35. Donos N, Kostopoulos L, Karring T. Augmentation of the mandible with GTR and onlay cortical bone grafting: An experimental study in the rat. Clin Oral Implants Res. 2002; 13:175-184.
36. Lundgren AK, Lundgren D, Sennerby L, Taylor A, Gottlow J, Nyman S. Augmentation of skull bone using a bioresorbable barrier supported by autologous bone grafts: An intraindividual study in the rabbit. Clin Oral Implants Res. 1997; 8:90-95. (Pubitemid 127688443)